Publications by authors named "Jianyun Deng"
Article Synopsis
- The study focuses on understanding the effectiveness of cetuximab, a targeting therapy, in treating esophageal squamous cell carcinoma (ESCC) patients, particularly those with overexpressed EGFR.
- A preclinical trial using 16 patient-derived xenografts (PDXs) found that 43.8% of these models responded positively to cetuximab, linked to specific genomic characteristics like high EGFR copy number and expression.
- The findings suggest that EGFR might serve as a reliable biomarker for determining which ESCC patients could benefit from cetuximab treatment, encouraging further clinical research.
Article Synopsis
- A preclinical trial found that 20% of gastric cancer patient-derived xenografts responded positively to the drug cetuximab.
- High levels of EGFR mRNA expression and a strong immunohistochemistry score (3+) were linked to reduced tumor growth.
- Among the responders, 50% showed EGFR amplification, indicating that certain gastric cancer subtypes with EGFR overexpression may benefit from cetuximab treatment.
Overall benefits of EGFR-TKIs are limited because these treatments are largely only for adenocarcinoma (ADC) with EGFR activating mutation. The treatments also usually lead to development of resistances. We have established a panel of patient-derived xenografts (PDXs) from treatment naïve Asian NSCLC patients, including those containing "classic" EGFR activating mutations.
View Article and Find Full Text PDFObjective: To characterize the features of radiographic abnormalities of the tibial bone in Wistar rats which have been fed T-2 toxin and Kashin-Beck disease (KBD) epidemic district food.
Methods: Ninety Wistar rats were divided into five groups. Group A was fed with a normal diet as control; group B was fed with a normal diet and T-2 toxin; group C was fed with a low-nutrition diet and T-2 toxin; group D was fed with a low-nutrition diet; and group E was fed with a KBD-affected diet.